- Home
- EXAS vs MKTX Comparison
EXAS vs MKTX Comparison
Compare EXAS & MKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EXAS | MKTX |
|---|---|---|
| Founded | 1995 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.0B | 6.0B |
| IPO Year | N/A | 2004 |
Fundamental Metrics
Financial Performance| Metric | EXAS | MKTX |
|---|---|---|
| Price | $101.36 | $181.34 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 10 |
| Target Price | $77.94 | ★ $211.80 |
| AVG Volume (30 Days) | ★ 10.3M | 673.5K |
| Earning Date | 11-03-2025 | 02-05-2026 |
| Dividend Yield | N/A | ★ 1.67% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 5.87 |
| Revenue | ★ $3,082,033,000.00 | $839,263,000.00 |
| Revenue This Year | $19.40 | $6.35 |
| Revenue Next Year | $13.51 | $8.31 |
| P/E Ratio | ★ N/A | $30.83 |
| Revenue Growth | ★ 14.47 | 3.37 |
| 52 Week Low | $38.81 | $156.17 |
| 52 Week High | $101.95 | $235.65 |
Technical Indicators
Market Signals| Indicator | EXAS | MKTX |
|---|---|---|
| Relative Strength Index (RSI) | 86.76 | 68.42 |
| Support Level | $101.30 | $179.20 |
| Resistance Level | $101.93 | $169.49 |
| Average True Range (ATR) | 0.35 | 3.85 |
| MACD | -1.30 | 1.84 |
| Stochastic Oscillator | 41.00 | 89.98 |
Price Performance
Historical ComparisonAbout EXAS Exact Sciences Corporation
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
About MKTX MarketAxess Holdings Inc.
Founded in 2000, MarketAxess is a leading electronic fixed-income trading platform that connects broker/dealers and institutional investors. The company is primarily focused on credit based fixed income securities with its main trading products being US investment-grade and high-yield bonds, Eurobonds, and Emerging Market corporate debt. Recently the company has expanded more aggressively into Treasuries and municipal bonds with the acquisitions of LiquidityEdge and MuniBrokers in 2019 and 2021, respectively. The company also provides pre- and post-trade services with its acquisition of Regulatory Reporting Hub from Deutsche Börse Group in 2020 adding to its product offerings.